Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease.
By P. Rutgeerts, B. Feagan, G. Lichtenstein, L. Mayer, Stefan Schreiber, J. Colombel, D. Rachmilewitz, D. Wolf, A. Olson, W. Bao and 1 more. Gastroenterology, 2004
998 citations recorded by the source corpus.
Subfields: Epidemiology, Genetics, Immunology
View Paper: https://www.semanticscholar.org/paper/5eebde28632b24b93839345e28c204497c2889aa
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
In Genetics
In Immunology
Citations in the corpus
- Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review (2009, methodology): “As an example, in the ACCENT I study, the median time to a loss of response was 19 weeks with placebo maintenance and 38 weeks with scheduled treatment (”
- Infliximab for induction and maintenance therapy for ulcerative colitis. (2005, neutral): “[15-18] However, the few small studies of infliximab in patients with active ulcerative colitis have yielded conflicting results.”
- Mucosal healing in inflammatory bowel diseases: a systematic review (2012, background): “Subsequent scheduled maintenance therapy with infliximab (every 8 weeks) led to mucosal healing in 44% of patients at week 54, compared to 18% given episodic treatment.(112) Although not all patients underwent control colonoscopies in these studies, it clearly suggested that induction and maintenanc”
- Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease (2012, background): “%) in CD. Levels 250 lg/g predicted endoscopic remission (CDEIS 3) with 94.1% sensitivity and 62.2% specificity (PPV 48.5%, NPV 96.6%).”
- Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. (2015, methodology): “CL IN IC AL AT administered as an intravenous infusion with weight-based dosing (5 mg/kg) and a regimen that includes an induction phase (intravenously at weeks 0, 2, and 6) followed by maintenance treatment (intravenously every 8 weeks) in responder patients.(3) Despite its proven efficacy, up to 6”